ASO Author Reflections: The Diminishing Role of Adjuvant HIPEC

Excerpt

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an established treatment strategy for peritoneal dissemination from many gastrointestinal malignancies. However, despite advances in understanding of the clinical progression of gastrointestinal neoplasms, it remains difficult to predict which patients with completed resected primary lesions and no peritoneal disease will ultimately progress to peritoneal metastases. HIPEC is currently being investigated in both gastric and colorectal malignancies as a potential strategy to prevent progression of these malignancies to peritoneal metastases in high-risk (HR) patients.1^–3 Our study evaluated outcomes of patients with appendiceal malignancies considered HR for intra-abdominal dissemination after primary resection, but no current evidence of peritoneal disease, who underwent adjuvant HIPEC. …